A prospective study of Ombitasvir/Paritaprevir/Ritonavir for chronic hepatitis C genotype 1b infected Japanese patients complicated with chronic kidney disease.
Phase of Trial: Phase IV
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 31 Jan 2017 New trial record